Close Menu

NEW YORK (360Dx) – iBio said today it and Oneway Diagnostica of Brazil have reached a deal to develop point-of-care diagnostic tests for Brazil with an initial focus on Zika and chikungunya.

As part of the deal, iBio will provide antigen and antibody manufacturing for product prototype development, regulatory approval, commercial launch, and ongoing commercialization efforts, while Oneway will manage marketing, distribution, and sales in Brazil.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.